Page last updated: 2024-11-12

monacolin j

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

monacolin J: isolated from Monascus ruber; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

monacolin J : A polyketide that is monacolin L bearing an additional hydroxy substituent at position 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9905162
CHEBI ID79034
SCHEMBL ID1820283
MeSH IDM0131965

Synonyms (21)

Synonym
p5iq0si56n ,
unii-p5iq0si56n
79952-42-4
monacolin j
2h-pyran-2-one, 6-(2-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)ethyl)tetrahydro-4-hydroxy-
antibiotic mb 530a
6(r)-[2-(8(s)-hydroxy]-2(s),6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydro-1(s)-naphthyl]ethyl-4(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one
lovastatin diol lactone
2h-pyran-2-one, 6-(2-((1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)ethyl)tetrahydro-4-hydroxy-, (4r,6r)-
AKOS022183350
monacolin j lactone
CHEBI:79034
(4r,6r)-4-hydroxy-6-{2-[(1s,2s,6r,8s,8ar)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl}tetrahydro-2h-pyran-2-one
SCHEMBL1820283
monakolin j
CS-0027590
HY-104051
Q15720548
ES-2535
lovastatin diol lactone ((4r,6r)-6-[2-[(1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl]ethyl]tetrahydro-4-hydroxy-2h-pyran-2-one)
DTXSID801031414

Research Excerpts

Overview

Monacolin J is a key precursor for the synthesis of simvastatin (Zocor), an important drug for treating hypercholesterolemia. It is also an intermediate of lovastatin biosynthesis.

ExcerptReferenceRelevance
"Monacolin J is a key precursor for the synthesis of simvastatin (Zocor), an important drug for treating hypercholesterolemia. "( Single-step production of the simvastatin precursor monacolin J by engineering of an industrial strain of Aspergillus terreus.
Huang, X; Liang, Y; Lu, X; Yang, Y, 2017
)
2.15
"Monacolin J is a key intermediate during simvastatin synthesis, and also an intermediate of lovastatin biosynthesis."( [One-step fermentation for producing simvastatin via RNAi silencing of lovF gene in Aspergillus terreus].
Huang, J; Li, M; Li, N; Yu, Z; Zhou, J, 2016
)
1.16
"Monacolin J is a key precursor for the synthesis of the cholesterol-lowering drug simvastatin. "( Construction of an Efficient and Robust Aspergillus terreus Cell Factory for Monacolin J Production.
Huang, X; Lu, X; Tang, S; Teng, Y; Yang, Y; Zheng, L; Zhu, J, 2019
)
2.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitorAny EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
carbobicyclic compoundA bicyclic compound in which all the ring atoms are carbon.
2-pyranonesA pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives.
hexahydronaphthalenesAny carbobycyclic compound that is an hexahydronaphthalene or a compound obtained from an hexahydronaphthalene by formal substitution of one or more hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (9.52)18.7374
1990's3 (14.29)18.2507
2000's5 (23.81)29.6817
2010's10 (47.62)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.06 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]